Payment overview · 2025
General Payments
$2,831.48
112 reported records · 23 companies
Healthcare provider profile · identity verified
George Gorich, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CARMEL, NY · NPI 1730125618
Verified facts
What the public records show
CMS Open Payments records show George Gorich, M.D. received $2,831.48 in general payments during 2025 across 112 reported records.
Lilly USA, LLC accounted for 16.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Belbuca, Eliquis, Kerendia, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Vraylar by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rytary by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 823 claims for Eliquis by this doctor in 2024.
Collegium Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BELBUCA as an associated drug or biological on 17475 records involving 4385 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Belbuca by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 308 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 823 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $468.99 | 16.6% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $280.79 | 9.9% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $264.99 | 9.4% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $236.42 | 8.3% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $233.03 | 8.2% | 14 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $178.68 | 6.3% | 10 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $148.00 | 5.2% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $136.61 | 4.8% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $136.33 | 4.8% | 5 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $121.08 | 4.3% | 4 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $100.75 | 3.6% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $99.87 | 3.5% | 4 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $98.76 | 3.5% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $53.05 | 1.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $48.64 | 1.7% | 2 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $45.74 | 1.6% | 2 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $42.75 | 1.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $42.50 | 1.5% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $21.84 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.84 | 0.7% | 1 | 2025 |
| Orexo US, Inc. | Unresolved — no canonical attribution shown | $18.61 | 0.7% | 1 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.60 | 0.6% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.61 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,788.73 | 110 |
| Education | $42.75 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $380.66 | 17 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $366.11 | 11 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $233.03 | 14 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $205.05 | 12 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $160.28 | 9 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $148.00 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $136.61 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $136.33 | 5 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $134.89 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $121.08 | 4 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $100.75 | 4 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $98.76 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $98.14 | 8 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $53.05 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $48.64 | 2 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $45.74 | 2 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $42.75 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $42.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $40.08 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.02 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $31.37 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $21.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Zubsolv Normalized: zubsolv |
Drug | Orexo US, Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Nucynta Normalized: nucynta |
Drug | Collegium Pharmaceutical, Inc. | $18.40 | 1 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $16.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Belbuca belbuca |
2025 | Belbuca | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 823 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 308 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
823 | 78 |
| Collegium Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | BELBUCA open payments reported associated product |
CMS Open Payments — General Payments 17475 supporting records · 4385 recipient NPIs · example record 1224105020 |
Belbuca · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
90 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
308 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
308 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
823 | 78 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 22 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1089 | 174 |
| Eliquis | Apixaban | 823 | 78 |
| Furosemide | Furosemide | 792 | 121 |
| Mirtazapine | Mirtazapine | 788 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 744 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 691 | 107 |
| Gabapentin | Gabapentin | 618 | 90 |
| Donepezil Hcl | Donepezil Hcl | 525 | 64 |
| Tramadol Hcl | Tramadol Hcl | 474 | 55 |
| Famotidine | Famotidine | 452 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 428 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 427 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 427 | 51 |
| Sertraline Hcl | Sertraline Hcl | 408 | 50 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 402 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 372 | 95 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 371 | 62 |
| Metformin Hcl | Metformin Hcl | 359 | 63 |
| Escitalopram Oxalate | Escitalopram Oxalate | 339 | 57 |
| Metoprolol Tartrate | Metoprolol Tartrate | 338 | 57 |
| Trazodone Hcl | Trazodone Hcl | 328 | 50 |
| Warfarin Sodium | Warfarin Sodium | 325 | suppressed |
| Lisinopril | Lisinopril | 317 | 52 |
| Losartan Potassium | Losartan Potassium | 315 | 51 |
| Memantine Hcl | Memantine Hcl | 309 | 42 |
| Rexulti | Brexpiprazole | 308 | 33 |
| Alprazolam | Alprazolam | 305 | 37 |
| Potassium Chloride | Potassium Chloride | 279 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 276 | 38 |
| Lorazepam | Lorazepam | 274 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 273 | 32 |
| Januvia | Sitagliptin Phosphate | 270 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 258 | 44 |
| Xarelto | Rivaroxaban | 250 | 21 |
| Simvastatin | Simvastatin | 242 | 41 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 226 | 21 |
| Clonazepam | Clonazepam | 212 | 27 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 198 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 195 | 35 |
| Finasteride | Finasteride | 193 | 31 |
| Mupirocin | Mupirocin | 192 | 76 |
| Pregabalin | Pregabalin | 192 | 19 |
| Carvedilol | Carvedilol | 186 | 35 |
| Azithromycin | Azithromycin | 178 | 105 |
| Prednisone | Prednisone | 177 | 45 |
| Levetiracetam | Levetiracetam | 166 | 27 |
| Latanoprost | Latanoprost | 162 | 30 |
| Spironolactone | Spironolactone | 151 | 27 |
| Omeprazole | Omeprazole | 147 | 36 |
| Olanzapine | Olanzapine | 146 | 13 |
| Methadone Hcl | Methadone Hcl | 139 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 136 | 34 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 136 | 17 |
| Baclofen | Baclofen | 129 | 17 |
| Divalproex Sodium | Divalproex Sodium | 129 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 126 | 14 |
| Meloxicam | Meloxicam | 119 | 27 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 117 | 48 |
| Sodium Chloride | 0.9 % Sodium Chloride | 108 | 27 |
| Bupropion Xl | Bupropion Hcl | 107 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 100 | 70 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 97 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 94 | 45 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 94 | 15 |
| Tradjenta | Linagliptin | 94 | suppressed |
| Diazepam | Diazepam | 93 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 91 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 19 |
| Insulin Lispro | Insulin Lispro | 90 | 19 |
| Jardiance | Empagliflozin | 90 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 30 |
| Novolog | Insulin Aspart | 85 | 16 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 85 | suppressed |
| Atenolol | Atenolol | 84 | 13 |
| Risperidone | Risperidone | 84 | 11 |
| Propranolol Hcl | Propranolol Hcl | 83 | 12 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 82 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | suppressed |
| Glipizide | Glipizide | 76 | 17 |
| Haloperidol | Haloperidol | 76 | suppressed |
| Ozempic | Semaglutide | 76 | 14 |
| Allopurinol | Allopurinol | 75 | 14 |
| Enalapril Maleate | Enalapril Maleate | 74 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 73 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 47 |
| Cephalexin | Cephalexin | 71 | 40 |
| Digoxin | Digoxin | 68 | suppressed |
| Ketoconazole | Ketoconazole | 68 | 22 |
| Midodrine Hcl | Midodrine Hcl | 68 | 14 |
| Santyl | Collagenase Clostridium Hist. | 68 | 31 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 66 | 18 |
| Valsartan | Valsartan | 66 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 64 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 64 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 63 | 15 |
| Hydromorphone Hcl | Hydromorphone Hcl | 60 | suppressed |
| Nystatin | Nystatin | 60 | 37 |
| Ezetimibe | Ezetimibe | 59 | 11 |
| Nifedipine Er | Nifedipine | 59 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 59 | suppressed |
| Entresto | Sacubitril/Valsartan | 57 | suppressed |
| Lactulose | Lactulose | 55 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | suppressed |
| Fentanyl | Fentanyl | 54 | suppressed |
| Hydrocortisone | Hydrocortisone | 54 | 27 |
| Timolol Maleate | Timolol Maleate | 52 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 51 | suppressed |
| Torsemide | Torsemide | 51 | 12 |
| Albuterol Sulfate | Albuterol Sulfate | 49 | 15 |
| Buspirone Hcl | Buspirone Hcl | 49 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 49 | suppressed |
| Vraylar | Cariprazine Hcl | 49 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Ibuprofen | Ibuprofen | 46 | 11 |
| Ondansetron Odt | Ondansetron | 46 | 20 |
| Silver Sulfadiazine | Silver Sulfadiazine | 46 | 19 |
| Budesonide | Budesonide | 45 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 24 |
| Fluconazole | Fluconazole | 45 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 12 |
| Ramipril | Ramipril | 45 | suppressed |
| Admelog Solostar | Insulin Lispro | 44 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 44 | 12 |
| Brilinta | Ticagrelor | 44 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 44 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 26 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 44 | 31 |
| Celecoxib | Celecoxib | 43 | 12 |
| Clonidine Hcl | Clonidine Hcl | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 42 | suppressed |
| Trulicity | Dulaglutide | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 13 |
| Belbuca | Buprenorphine Hcl | 40 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 40 | suppressed |
| Telmisartan | Telmisartan | 40 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 39 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 38 | 18 |
| Ceftriaxone | Ceftriaxone Sodium | 37 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 17 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 36 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Enulose | Lactulose | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | 28 |
| Procrit | Epoetin Alfa | 34 | suppressed |
| Ssd | Silver Sulfadiazine | 34 | 14 |
| Diltiazem 24hr Er | Diltiazem Hcl | 33 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Irbesartan | Irbesartan | 32 | suppressed |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 31 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 31 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 30 | suppressed |
| Galantamine Er | Galantamine Hbr | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 24 |
| Vancomycin Hcl | Vancomycin Hcl | 30 | 11 |
| Clonidine | Clonidine | 29 | suppressed |
| Nystop | Nystatin | 29 | 13 |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 29 | 19 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 27 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 25 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 25 | suppressed |
| Lacosamide | Lacosamide | 25 | suppressed |
| Rytary | Carbidopa/Levodopa | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 24 | suppressed |
| Acetylcysteine | Acetylcysteine | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 19 |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 22 |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Erythromycin | Erythromycin Base | 22 | 11 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 22 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Alphagan P | Brimonidine Tartrate | 21 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Cyclosporine | Cyclosporine | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Letrozole | Letrozole | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Anastrozole | Anastrozole | 20 | suppressed |
| Buprenorphine | Buprenorphine | 20 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 20 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 20 | suppressed |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Tobramycin | Tobramycin | 20 | 15 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | 14 |
| Scopolamine | Scopolamine | 18 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 18 | 14 |
| Dextrose In Water | Dextrose 5 % In Water | 17 | 11 |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Restasis | Cyclosporine | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Tacrolimus | Tacrolimus | 16 | suppressed |
| Admelog | Insulin Lispro | 15 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 14 | suppressed |
| Lumigan | Bimatoprost | 14 | suppressed |
| Meropenem | Meropenem | 14 | 11 |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 14 | 13 |
| Prednisolone Acetate | Prednisolone Acetate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Clozapine Odt | Clozapine | 13 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Leflunomide | Leflunomide | 13 | suppressed |
| Nucynta Er | Tapentadol Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Dilantin | Phenytoin | 12 | suppressed |
| Konvomep | Omeprazole/Sodium Bicarbonate | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tobradex St | Tobramycin/Dexamethasone | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,831.48 · 112 records | Lilly USA, LLC | BRIXADI, Belbuca, CAPLYTA, CONTRAVE, CREXONT, ELIQUIS, IMCIVREE, KISUNLA, Kerendia, Leqembi, MOUNJARO, NURTEC ODT, Nucynta, Ozempic, QULIPTA, RAYALDEE, REBLOZYL, REXULTI, REZDIFFRA, SUBLOCADE, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VELPHORO, VIVITROL, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND, Zubsolv | 19 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Belbuca play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error